Celecoxib for the Prevention of Sporadic Colorectal AdenomasMonica M. Bertagnolli, Ernest T. Hawk, Craig Eagle et al.|New England Journal of Medicine|2006Cited by 1k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S. Davids, John F. Gerecitano, Andrew W. Roberts et al.|Journal of Clinical Oncology|2017Cited by 752
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.Joyce O’Shaughnessy, Daniel D. Von Hoff, William G. Nelson et al.|PubMed|2002Cited by 383
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Andrew W. Roberts, Shuo Ma et al.|The Lancet Oncology|2017Cited by 327
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, William G. Wierda, Barbara Eichhorst et al.|Journal of Clinical Oncology|2018Cited by 313